Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid (RESPECT-EPA)
Abstract
BACKGROUND:
Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to assess the clinical benefits of icosapent ethyl in patients with coronary artery disease, a low EPA/arachidonic acid (AA) ratio, and statin treatment.
METHODS:
In this prospective, multicenter, randomized, open-label, blinded end-point study, patients with stable coronary artery disease and a low EPA/AA ratio (<0.4) were randomized to EPA (1800 of icosapent ethyl administered daily) or control group. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, unstable angina pectoris, and coronary revascularization. The secondary composite end points of coronary events included sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina requiring emergency hospitalization and coronary revascularization, or coronary revascularization.
RESULTS:
Overall, 3884 patients were enrolled at 95 sites in Japan. Among them, 2506 patients had a low EPA/AA ratio, and 1249 and 1257 patients were randomized to the EPA and control group, respectively. The median EPA/AA ratio was 0.243 (interquartile range, 0.180–0.314) and 0.235 (interquartile range, 0.163–0.310) in the EPA and control group, respectively. Over a median period of 5 years, the primary end point occurred in 112 of 1225 patients (9.1%) and 155 of 1235 patients (12.6%) in the EPA and control group, respectively (hazard ratio, 0.79 [95% CI, 0.62–1.00]; P=0.055). Meanwhile, the secondary composite end point of coronary events in the EPA group was significantly lower (81/1225 [6.6%] versus 120/1235 [9.7%] patients; hazard ratio, 0.73 [95% CI, 0.55–0.97]). Adverse events did not differ between the groups, but the rate of new-onset atrial fibrillation was significantly higher in the EPA group (3.1% versus 1.6%; P=0.017).
CONCLUSIONS:
Icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not reach statistical significance in patients with chronic coronary artery disease, a low EPA/AA ratio, and statin treatment.
REGISTRATION:
URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000012069.
Get full access to this article
View all available purchase options and get full access to this article.
Supplemental Material
REFERENCES
1.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1
2.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5
3.
Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. doi: 10.1016/S0140-6736(14)61368-4
4.
Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40:1135–1147. doi: 10.1161/ATVBAHA.119.313286
5.
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al; Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098. doi: 10.1016/S0140-6736(07)60527-3
6.
Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–343. doi: 10.1016/j.jacc.2018.04.061
7.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. doi: 10.1056/NEJMoa1812792
8.
Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268–2280. doi: 10.1001/jama.2020.22258
9.
Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047–2067. doi: 10.1016/j.jacc.2011.06.063
10.
Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, et al; JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009;73:1283–1290. doi: 10.1253/circj.cj-08-1197
11.
Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J. 2012;76:423–429. doi: 10.1253/circj.cj-11-0941
12.
Nelson JR, Raskin S. The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgrad Med. 2019;131:268–277. doi: 10.1080/00325481.2019.1607414
13.
Abe S, Sugimura H, Watanabe S, Murakami Y, Ebisawa K, Ioka T, Takahashi T, Ando T, Kono K, Inoue T. Eicosapantaenoic acid treatment based on the EPA/AA ratio in patients with coronary artery disease: follow-up data from the Tochigi Ryomo EPA/AA Trial in Coronary Artery Disease (TREAT-CAD) study. Hypertens Res. 2018;41:939–946. doi: 10.1038/s41440-018-0102-9
14.
Nishizaki Y, Miyauchi K, Iwata H, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, et al. Study protocol and baseline characteristics of randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J. 2022;257:1–8. doi: 10.1016/j.ahj.2022.11.008
15.
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, et al; Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan: 2012 version. J Atheroscler Thromb. 2013;20:517–523. doi: 10.5551/jat.15792
16.
Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, et al; Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846–984. doi: 10.5551/jat.GL2017
17.
Kalbfleisch, JD, Prentice, RL. The Statistical Analysis of Failure Time Data. Wiley; 2011.
18.
Hasegawa T, Otsuka K, Iguchi T, Matsumoto K, Ehara S, Nakata S, Nishimura S, Kataoka T, Shimada K, Yoshiyama M. Serum n-3 to n-6 polyunsaturated fatty acids ratio correlates with coronary plaque vulnerability: an optical coherence tomography study. Heart Vessels. 2014;29:596–602. doi: 10.1007/s00380-013-0404-4
19.
Nagahara Y, Motoyama S, Sarai M, Ito H, Kawai H, Takakuwa Y, Miyagi M, Shibata D, Takahashi H, Naruse H, et al. Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease. Atherosclerosis. 2016;250:30–37. doi: 10.1016/j.atherosclerosis.2016.04.026
20.
Kuriki K, Nagaya T, Tokudome Y, Imaeda N, Fujiwara N, Sato J, Goto C, Ikeda M, Maki S, Tajima K, et al. Plasma concentrations of (n-3) highly unsaturated fatty acids are good biomarkers of relative dietary fatty acid intakes: a cross-sectional study. J Nutr. 2003;133:3643–3650. doi: 10.1093/jn/133.11.3643
21.
Bostrom JA, Beckman JA, Berger JS. Summoning STRENGTH to question the placebo in REDUCE-IT. Circulation. 2021;144:407–409. doi: 10.1161/CIRCULATIONAHA.121.054539
22.
Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase a2: a REDUCE-IT biomarker substudy. Circulation. 2022;146:372–379. doi: 10.1161/CIRCULATIONAHA.122.059410
23.
Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137:1997–2009. doi: 10.1161/CIRCULATIONAHA.117.032615
24.
Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, Inada T, Mitsuoka H, Taniguchi R, Nakano A, et al; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: perspectives from the COREDO-Kyoto Registry Cohort-2. Circ J. 2012;76:1369–1379. doi: 10.1253/circj.cj-11-1356
25.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453–463. doi: 10.1016/S1474-4422(09)70058-4
26.
Kim H, Kim JT, Lee JS, Kim BJ, Kang J, Lee KJ, Park JM, Kang K, Lee SJ, Kim JG, et al. Stroke of other determined etiology: results from the nationwide multicenter stroke registry. Stroke. 2022;53:2597–2606. doi: 10.1161/STROKEAHA.121.037582
27.
Kim BJ, Kim JS. Ischemic stroke subtype classification: an Asian viewpoint. J Stroke. 2014;16:8–17. doi: 10.5853/jos.2014.16.1.8
28.
Miyagawa N. The ratio of circulating eicosapentaenoic acid to arachidonic acid ratio in the community-dwelling Japanese population. J Atheroscler Thromb. 2023;30:587–588. doi: 10.5551/jat.ED222
29.
Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925–3932. doi: 10.1093/eurheartj/ehaa652
30.
Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131–3140. doi: 10.1016/j.bbamem.2016.10.002
Information & Authors
Information
Published In
Copyright
© 2024 American Heart Association, Inc.
Versions
You are viewing the most recent version of this article.
History
Received: 9 May 2023
Accepted: 24 May 2024
Published online: 14 June 2024
Published in print: 6 August 2024
Keywords
Subjects
Authors
Disclosures
Dr Miyauchi has received lecture fees from Amgen Astellas BioPharma, Astellas Pharma, MSD, Bayer Yakuhin, Sanofi, Takeda Pharmaceutical, Daiichi-Sankyo, Nippon Boehringer Ingelheim, and Bristol-Myers Squibb. Dr Iwata has received lecture fees from Kowa, Daiichi-Sankyo, Sumitomo Pharma, MSD, Novo Nordisk, Mochida Pharmaceutical, and Bayer Yakuhin. Dr Hirayama has received lecture fees from Bayer Yakuhin and Daiichi-Sankyo. Dr Kimura has received grants from Bayer Yakuhin, consulting fees from Idorsia Pharmaceuticals Japan, and lecture fees from Bayer Yakuhin and Daiichi-Sankyo. Dr Ozaki has received grants from Takeda Pharmaceutical, Daiichi-Sankyo, and Otsuka Pharmaceutical. Dr Murohara has received from Daiichi-Sankyo, Jansen Pharmaceutical, Bayer Yakuhin, Ono Pharmaceutical, Mochida Pharmaceutical, Pfizer, AstraZeneca, and Boehringer Ingelheim Japan. Dr Daida has received grants from Philips Japan, FUJIFILM Holdings Corp, Asahi Kasei Corp, Inter Reha, TOHO HOLDINGS, GLORY, Bristol-Myers Squibb, Abbott Japan, Boehringer Ingelheim Japan, Eisai, Bayer Yakuhin, and Daiichi-Sankyo, as well as lecture fees from Novartis Pharma, Bayer Yakuhin, Sanofi, Kowa, Taisho Pharmaceutical, Abbott Medical Japan, Otsuka Pharmaceutical, Amgen, MSD, Daiichi-Sankyo, Pfizer Japan, FUKUDA DENSHI, Tsumura, and TOA EIYO. The other authors report no conflicts.
Sources of Funding
This study was supported by a grant from the Japan Heart Foundation, Japan.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Research progress of two-pore potassium channel in myocardial ischemia-reperfusion injury, Frontiers in Physiology, 15, (2024).https://doi.org/10.3389/fphys.2024.1473501
- Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention, Circulation, 150, 6, (435-438), (2024)./doi/10.1161/CIRCULATIONAHA.124.069881
- Omega-3 Fatty Acids and Arrhythmias, Circulation, 150, 6, (488-503), (2024)./doi/10.1161/CIRCULATIONAHA.123.065769
- “A Time to Tear Down and a Time to Mend”: The Role of Eicosanoids in Atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, 44, 11, (2258-2263), (2024)./doi/10.1161/ATVBAHA.124.319570
- ▼Icosapent ethyl for CV risk reduction, Drug and Therapeutics Bulletin, 62, 9, (135-140), (2024).https://doi.org/10.1136/dtb.2024.000038
- Diet and risk of atrial fibrillation: a systematic review, European Heart Journal, 45, 40, (4259-4274), (2024).https://doi.org/10.1093/eurheartj/ehae551
- Inflammation and resolution in obesity, Nature Reviews Endocrinology, (2024).https://doi.org/10.1038/s41574-024-01047-y
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.